Follow The Filings

AVTX Avalo Therapeutics Inc.

Health Care, filed as AVALO THERAPEUTICS INC (COM NEW), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3

  • 1 Owner
  • Max 0.3%
  • $61M
  • 1 add

In 2026 Q3 Farallon Capital Management added to Avalo Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Add 0.26%

Who owns AVTX

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 0.26%, was 0.21% Add +59.1% 3,974,000 $61M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AVTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AVTX insider trades
  • None no insider bought on the open market
  • $52K sold by 1 insider outside a trading plan
  • $8.3M sold by 4 insiders under 10b5-1 plans
  1. Christopher Ryan Sullivan CFO
    Planned sale
    $202K 12,394 shares at $16.33 24% of stake
    Traded Sep 16 Filed Sep 18
  2. Christopher Ryan Sullivan CFO
    Planned sale
    $179K 10,185 shares at $17.62 20% of stake
    Traded Sep 10 Filed Sep 11
  3. Mittie Doyle Chief Medical Officer
    Planned sale
    $14K 679 shares at $20.00 1.3% of stake
    Traded Aug 28 Filed Sep 1
  4. Mittie Doyle Chief Medical Officer
    Planned sale
    $20K 1,000 shares at $20.00 1.9% of stake
    Traded Aug 17 Filed Aug 19
  5. Christopher Ryan Sullivan CFO
    Planned sale
    $1.5M 72,725 shares at $19.94 65% of stake
    Traded Aug 17–18 Filed Aug 19
  6. Jennifer Riley Chief Strategy Officer
    Sale
    $52K 2,655 shares at $19.59 6.7% of stake
    Traded Aug 11 Filed Aug 12
  7. Mittie Doyle Chief Medical Officer
    Planned sale
    $14K 679 shares at $20.00 1.3% of stake
    Traded Aug 10 Filed Aug 12
  8. Mittie Doyle Chief Medical Officer
    Planned sale
    $20K 1,000 shares at $20.00 1.9% of stake
    Traded Jul 27 Filed Jul 29
  9. Mittie Doyle Chief Medical Officer
    Planned sale
    $93K 4,654 shares at $20.00 8.2% of stake
    Traded Jun 30 Filed Jul 2
  10. Mittie Doyle Chief Medical Officer
    Planned sale
    $26K 1,450 shares at $18.00 2.7% of stake
    Traded Jun 23 Filed Jun 25
  11. Mittie Doyle Chief Medical Officer
    Planned sale
    $11K 679 shares at $16.00 1.4% of stake
    Traded May 28 Filed Jun 1
  12. Mittie Doyle Chief Medical Officer
    Planned sale
    $56K 3,000 shares at $18.76 45% of stake
    Traded May 15 Filed May 19
  13. Christopher Ryan Sullivan CFO
    Planned sale
    $449K 18,606 shares at $24.12 98% of stake
    Traded May 7 Filed May 11
  14. Mittie Doyle Chief Medical Officer
    Planned sale
    $2.2M 108,234 shares at $20.61 97% of stake
    Traded May 5–6 Filed May 7
  15. Christopher Ryan Sullivan CFO
    Planned sale
    $949K 47,000 shares at $20.19 99% of stake
    Traded May 6 Filed May 7

Also filed in the last 12 months, not counted as buying or selling: 33 option exercises, 10 share withholdings for taxes, and 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
424B5
8-K 1.01,1.02,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
424B3

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.92M $0.441M $0.059M
Gross profit * $640,000 — —
Gross margin * 33.3% — —
Net income -$31.54M -$35.13M -$78.26M
Net margin * -1639.5% -7965.8% -132642.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $8.4M $138.89M $105.29M
Total non-current assets * $12.6M $11.84M $11.17M
Total assets $20.99M $150.73M $116.46M
Total current liabilities $4.62M $6.96M $12.94M
Total non-current liabilities * $9.07M $10.74M $20.47M
Total equity $7.3M $133.03M $83.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$30.68M -$49.06M -$51.46M
Cash from investing -$0.133M $0.356M -$81.72M
Cash from financing $25.04M $175.85M $14.59M
Net change in cash -$5.77M $127.15M -$118.59M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf